Multitarget strategies in Alzheimer's disease: benefits and challenges on the road to therapeutics.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Future Medicinal Chemistry

• Publication date

  2016-04-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.4155/fmc-2016-0003PMID 27079260
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nature‐Inspired Multifunctional Ligands: Focusing on Amyloid‐Based Molecular Mechanisms of Alzheimer's Disease

  2016cited by this paper
• Development and Application of a Virtual Screening Protocol for the Identification of Multitarget Fragments

  2016cited by this paper
• Multitarget Strategy to Address Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and Computational Studies of Coumarin‐Based Derivatives

  2016cited by this paper
• Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression

  2016cited by this paper
• Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β‐amyloid in ageing and Alzheimer's disease

  2016cited by this paper
• Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies

  2016cited by this paper
• Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3β inhibitors.

  2015cited by this paper
• 3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer's Disease.

  2015cited by this paper
• Donepezil-ferulic acid hybrids as anti-Alzheimer drugs.

  2015cited by this paper
• Neuroinflammation in Alzheimer's disease.

  2015cited by this paper
• Tools of the Trade: Investigations into Design Strategies of Small Molecules to Target Components in Alzheimer's Disease

  2015cited by this paper
• Novel Levetiracetam Derivatives That Are Effective against the Alzheimer-like Phenotype in Mice: Synthesis, in Vitro, ex Vivo, and in Vivo Efficacy Studies.

  2015cited by this paper
• Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets To Promote Axon Growth.

  2015cited by this paper
• Novel multitarget-directed ligands (MTDLs) with acetylcholinesterase (AChE) inhibitory and serotonergic subtype 4 receptor (5-HT4R) agonist activities as potential agents against Alzheimer's disease: the design of donecopride.

  2015cited by this paper
• From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer's Disease.

  2015cited by this paper
• Dual inhibition of acetylcholinesterase and butyrylcholinesterase enzymes by allicin

  2015cited by this paper
• Perspectives on Inhibiting β‐Amyloid Aggregation through Structure‐Based Drug Design

  2015cited by this paper
• Aβ regulation-based multitarget strategy for drug discovery against Alzheimer’s disease

  2015cited by this paper
• Conjugates of γ-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease

  2015cited by this paper
• The case for rejecting the amyloid cascade hypothesis

  2015cited by this paper
• Role of sigma-1 receptors in neurodegenerative diseases.

  2015cited by this paper
• Multitarget Therapeutic Leads for Alzheimer’s Disease: Quinolizidinyl Derivatives of Bi‐ and Tricyclic Systems as Dual Inhibitors of Cholinesterases and β‐Amyloid (Aβ) Aggregation

  2015cited by this paper
• The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives.

  2014cited by this paper
• Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects.

  2014cited by this paper
• Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease.

  2014cited by this paper
• First selective dual inhibitors of tau phosphorylation and Beta-amyloid aggregation, two major pathogenic mechanisms in Alzheimer's disease.

  2014cited by this paper
• Oxidative stress in Alzheimer's disease: are we connecting the dots?

  2014cited by this paper
• Development of dual targeting inhibitors against aggregations of amyloid-β and tau protein.

  2014cited by this paper
• Polypharmacology: challenges and opportunities in drug discovery.

  2014cited by this paper
• Polypharmacology: the rise of multitarget drugs over combination therapies.

  2014cited by this paper
• GSK-3β, a pivotal kinase in Alzheimer disease

  2014cited by this paper
• Shogaol-huprine hybrids: dual antioxidant and anticholinesterase agents with β-amyloid and tau anti-aggregating properties.

  2014cited by this paper
• Effects of novel monoamine oxidases and cholinesterases targeting compounds on brain neurotransmitters and behavior in rat model of vascular dementia.

  2014cited by this paper
• Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment

  2014cited by this paper
• Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer's disease.

  2014cited by this paper
• Multi-target Design Strategies in the Context of Alzheimer’s Disease: Acetylcholinesterase Inhibition and NMDA Receptor Antagonism as the Driving Forces

  2014cited by this paper
• Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.

  2014cited by this paper
• Synthesis and multitarget biological profiling of a novel family of rhein derivatives as disease-modifying anti-Alzheimer agents.

  2014cited by this paper
• Recent Development of Multifunctional Agents as Potential Drug Candidates for the Treatment of Alzheimer's Disease

  2014cited by this paper
• Zyxin is a novel target for beta‐amyloid peptide: characterization of its role in Alzheimer's pathogenesis

  2013cited by this paper
• Amyloid β, Glutamate, Excitotoxicity in Alzheimer's Disease: Are We on the Right Track?

  2013cited by this paper
• Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer’s disease

  2013cited by this paper
• Editorial (Hot Topic: Complexity against Complexity: Multitarget Drugs)

  2013cited by this paper
• The Bivalent Ligand Approach as a Tool for Improving the in vitro Anti‐Alzheimer Multitarget Profile of Dimebon

  2013cited by this paper
• Untangling amyloid-β, tau, and metals in Alzheimer's disease.

  2013cited by this paper
• Dual inhibitors of β-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates.

  2013cited by this paper
• Polypharmacology in a single drug: multitarget drugs.

  2013cited by this paper
• Multipotent, permeable drug ASS234 inhibits Aβ aggregation, possesses antioxidant properties and protects from Aβ-induced apoptosis in vitro.

  2013cited by this paper
• Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease

  2013cited by this paper
• Propargylamine-derived multitarget-directed ligands: fighting Alzheimer’s disease with monoamine oxidase inhibitors

  2013cited by this paper
• Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer's disease.

  2013cited by this paper
• Multifunctional tacrine derivatives in Alzheimer's disease.

  2013cited by this paper
• Complexity against complexity: multitarget drugs.

  2013cited by this paper
• A new roadmap for drug development for Alzheimer's disease

  2013cited by this paper
• Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease

  2013cited by this paper
• Blockade of Tau Hyperphosphorylation and Aβ1–42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer’s Disease

  2013cited by this paper
• Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5-HT(4) receptor activation (RS67333) on object recognition in mice.

  2012cited by this paper
• Automated design of ligands to polypharmacological profiles

  2012cited by this paper
• The role of fragment-based and computational methods in polypharmacology.

  2012cited by this paper
• The serotonergic system in ageing and Alzheimer's disease.

  2012cited by this paper
• The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?

  2012cited by this paper
• Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease.

  2012cited by this paper
• Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo

  2012cited by this paper
• Conformational Altered p53 as an Early Marker of Oxidative Stress in Alzheimer's Disease

  2012cited by this paper
• From Anti-Parkinson's Drug Rasagiline to Novel Multitarget Iron Chelators with Acetylcholinesterase and Monoamine Oxidase Inhibitory and Neuroprotective Properties for Alzheimer's Disease

  2012cited by this paper
• Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.

  2011cited by this paper
• Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.

  2011cited by this paper
• Control of p53 and NF-κB signaling by WIP1 and MIF: role in cellular senescence and organismal aging.

  2011cited by this paper
• Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.

  2011cited by this paper
• The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-β42 with memantine.

  2011cited by this paper
• Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease.

  2011cited by this paper
• The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

  2011cited by this paper
• Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease

  2011cited by this paper
• Pharmacology. The puzzling rise and fall of a dark-horse Alzheimer's drug.

  2010cited by this paper
• Alzheimer's disease: strategies for disease modification

  2010cited by this paper
• Beyond the Cholinergic Hypothesis: Do Current Drugs Work in Alzheimer's Disease?

  2010cited by this paper
• Beta-amyloid: a disease target or a synaptic regulator affecting age-related neurotransmitter changes?

  2010cited by this paper
• Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.

  2010cited by this paper
• The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics

  2009cited by this paper
• Alzheimer's disease: new approaches to drug discovery.

  2009cited by this paper
• Assessment of MAO‐B Occupancy in the Brain With PET and [11C]‐L‐Deprenyl‐D2: A Dose‐Finding Study With a Novel MAO‐B Inhibitor, EVT 301

  2009cited by this paper
• Alzheimer's disease: from pathology to therapeutic approaches.

  2009cited by this paper
• Designing multiple ligands - medicinal chemistry strategies and challenges.

  2009cited by this paper
• The Novel Cholinesterase–Monoamine Oxidase Inhibitor and Antioxidant, Ladostigil, Confers Neuroprotection in Neuroblastoma Cells and Aged Rats

  2009cited by this paper
• The neuroprotective mechanism of action of the multimodal drug ladostigil.

  2008cited by this paper
• The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity.

  2008cited by this paper
• Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease.

  2008cited by this paper
• A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory.

  2008cited by this paper
• Multi-target-directed ligands to combat neurodegenerative diseases.

  2008cited by this paper
• Functional Convergence of Dopaminergic and Cholinergic Input Is Critical for Hippocampus-Dependent Working Memory

  2008cited by this paper
• Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush.

  2008cited by this paper
• Prucalopride and donepezil act synergistically to reverse scopolamine-induced memory deficit in C57Bl/6j mice.

  2008cited by this paper
• Network pharmacology: the next paradigm in drug discovery.

  2008cited by this paper
• A role for the 5-HT1A, 5-HT4 and 5-HT6 receptors in learning and memory

  2008cited by this paper
• Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival.

  2007cited by this paper
• Does Serotonin Augmentation Have Any Effect on Cognition and Activities of Daily Living in Alzheimer's Dementia?: A Double-Blind, Placebo-Controlled Clinical Trial

  2007cited by this paper
• Induction of Neurotrophic Factors GDNF and BDNF Associated with the Mechanism of Neurorescue Action of Rasagiline and Ladostigil

  2007cited by this paper
• Therapies for Alzheimer's disease

  2007cited by this paper
• 5-HT4 receptor and Alzheimer's disease: the amyloid connection.

  2007cited by this paper
• 100 Years and Counting: Prospects for Defeating Alzheimer's Disease

  2006cited by this paper

• Pyranotacrines as prospective multi-target compounds against Alzheimer's disease.

  2025cites this paper
• Axially Quinoline-Substituted Silicon Phthalocyanines: Synthesis, Characterization, Molecular Modeling and Biological Evaluation against Cholinesterases and Carbonic Anhydrases

  2025cites this paper
• Unveiling new thiazole‐clubbed piperazine derivatives as multitarget anti‐AD: Design, synthesis, and in silico studies

  2024cites this paper
• Design, synthesis and evaluation of imidazo[1,2-a]pyrazin-8(7H)-one derivatives as acetylcholinesterase inhibitors and antioxidants

  2024cites this paper
• Application of the Mannich reaction in the structural modification of natural products

  2023cites this paper
• Modified Tacrine Derivatives as Multitarget-Directed Ligands for the Treatment of Alzheimer’s Disease: Synthesis, Biological Evaluation, and Molecular Modeling Study

  2023cites this paper
• Elaboration of the Effective Multi-Target Therapeutic Platform for the Treatment of Alzheimer’s Disease Based on Novel Monoterpene-Derived Hydroxamic Acids

  2023cites this paper
• Chalcones bearing nitrogen‐containing heterocyclics as multi‐targeted inhibitors: Design, synthesis, biological evaluation and molecular docking studies

  2023cites this paper
• Memantine and its role in parkinsonism, seizure, depression, migraine headache, and Alzheimer’s disease

  2023cites this paper
• Intranasal Drug Delivery by Nanotechnology: Advances in and Challenges for Alzheimer’s Disease Management

  2023cites this paper
• Computational Studies to Understand the Neuroprotective Mechanism of Action Basil Compounds

  2023cites this paper
• Design, Synthesis, and Proof of Concept of Balanced Dual Inhibitors of Butyrylcholinesterase (BChE) and Histone Deacetylase 6 (HDAC6) for the Treatment of Alzheimer's Disease.

  2023cites this paper
• Near-Infrared Fluorescent Probes as Imaging and Theranostic Modalities for Amyloid-Beta and Tau Aggregates in Alzheimer's Disease.

  2022cites this paper
• Would the Development of a Multitarget Inhibitor of 3CLpro and TMPRSS2 be Promising in the Fight Against SARS-CoV-2?

  2022cites this paper
• Novel Multipotent Amantadine-M30D Hybrids with Highly Selective Butyrylcholinesterase Inhibition and Neuroprotective Effects as Effective Anti-Alzheimer's Agents.

  2022cites this paper
• Design, synthesis and structure-activity relationship studies of 3-phenylpyrazino[1,2-a]indol-1(2H)-ones as amyloid aggregation and cholinesterase inhibitors with antioxidant activity

  2022cites this paper
• Synthesis and biological evaluation of 4-hydroxy-methylpiperidinyl-N-benzyl-acylarylhydrazone hybrids designed as novel multifunctional drug candidates for Alzheimer's disease.

  2022cites this paper
• Structure-based design of novel donepezil-like hybrids for a multi-target approach to the therapy of Alzheimer's disease.

  2022cites this paper
• Acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease – a patent review (2016–present)

  2021cites this paper
• Rudimentary Pharmacological Inspection of the Ethanolic Extract of Grewia hirsute Vhal

  2021cites this paper
• A new mode of Thinfilm and Nanofiber for burst release of the drug for Alzheimer disease; A complete scenario from dispersible polymer to formulation methodology.

  2021cites this paper
• Multifaceted Alzheimer’s Disease: Building a Roadmap for Advancement of Novel Therapies

  2021cites this paper
• Huprine Y - tryptophan heterodimers with potential implication to Alzheimer's disease treatment.

  2021cites this paper
• Cholinesterase inhibitory potential of Dillenia suffruticosa chemical constituents and protective effect against Aβ−induced toxicity in transgenic Caenorhabditis elegans model

  2021cites this paper
• Design, synthesis, and in vitro evaluation of 4-aminoalkyl-1(2H)-phthalazinones as potential multifunctional anti-Alzheimer's disease agents.

  2021cites this paper
• Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer's disease.

  2021cites this paper
• Derivatives of Tenuazonic Acid as Potential New Multi-Target Anti-Alzheimer’s Disease Agents

  2021cites this paper
• Multitarget Biological Profiling of New Naphthoquinone and Anthraquinone-Based Derivatives for the Treatment of Alzheimer’s Disease

  2021cites this paper
• Design, synthesis and evaluation of new 4-arylthiazole-2-amine derivatives as acetylcholinesterase inhibitors.

  2020cites this paper
• Strategies targeting soluble β-Amyloid oligomers and their application to early diagnosis of Alzheimer's Disease.

  2020cites this paper
• Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands.

  2020cites this paper
• Discovery of small molecules for the treatment of Alzheimer’s disease

  2020cites this paper
• Structure-Based Discovery of Dual-Target Hits for Acetylcholinesterase and the α7 Nicotinic Acetylcholine Receptors: In Silico Studies and In Vitro Confirmation

  2020cites this paper
• Identification of New Targets and the Virtual Screening of Lignans against Alzheimer's Disease

  2020cites this paper
• Memantine Derivatives as Multitarget Agents in Alzheimer’s Disease

  2020cites this paper
• Design, synthesis, biological evaluation, and docking study of novel dual-acting thiazole-pyridiniums inhibiting acetylcholinesterase and β-amyloid aggregation for Alzheimer's disease.

  2020cites this paper
• Novel tacrine-tryptophan hybrids: Multi-target directed ligands as potential treatment for Alzheimer's disease.

  2019cites this paper
• Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.

  2019cites this paper
• Neuroprotection and improvement of the histopathological and behavioral impairments in a murine Alzheimer's model treated with Zephyranthes carinata alkaloids.

  2019cites this paper
• Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential

  2019cites this paper
• Flurbiprofen-chalcone hybrid Mannich base derivatives as balanced multifunctional agents against Alzheimer's disease: Design, synthesis and biological evaluation.

  2019cites this paper
• Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.

  2019cites this paper
• Search for multifunctional agents against Alzheimer's disease among non-imidazole histamine H3 receptor ligands. In vitro and in vivo pharmacological evaluation and computational studies of piperazine derivatives.

  2019cites this paper
• Gracilin A derivatives target early events in Alzheimer's disease: in vitro effects on neuroinflammation and oxidative stress.

  2019cites this paper
• Recent Advances in the Quest for Treatment and Management of Alzheimer and Other Dementia

  2019cites this paper
• Advancement of multi-target drug discoveries and promising applications in the field of Alzheimer's disease.

  2019cites this paper
• Multi-target design strategies for the improved treatment of Alzheimer's disease.

  2019cites this paper
• Synthesis and Biological Evaluation of Novel Chromone+Donepezil Hybrids for Alzheimer's Disease Therapy.

  2019cites this paper
• Streptocyclinones A and B ameliorate Alzheimer's disease pathological processes in vitro

  2018cites this paper
• Effets de l’administration de tétrahydrobioptérine en condition physiologique et pathologique : De la neurobiologie au comportement

  2018cites this paper
• Chemical Diversity in the G Protein-Coupled Receptor Superfamily.

  2018cites this paper
• Insights into the Molecular Mechanisms of Alzheimer’s and Parkinson’s Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology

  2018cites this paper
• The involvement of the brain microenvironment in Alzheimer’s Disease

  2018cites this paper
• Natural Products and Chemical Biology Tools: Alternatives to Target Epigenetic Mechanisms in Cancers.

  2018cites this paper
• Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer's Disease.

  2018cites this paper
• Design, Synthesis, and Biological Evaluation of Dual-Target Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 9A (PDE9A) for the Treatment of Alzheimer's Disease.

  2018cites this paper
• Design and synthesis of multipotent 3-aminomethylindoles and 7-azaindoles with enhanced protein phosphatase 2A-activating profile and neuroprotection.

  2018cites this paper
• Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease.

  2018cites this paper
• Acetylcholinesterase and Aβ Aggregation Inhibition by Heterometallic Ruthenium(II)-Platinum(II) Polypyridyl Complexes.

  2018cites this paper
• Design, Synthesis, and Biological Evaluation of 2-(Benzylamino-2-Hydroxyalkyl)Isoindoline-1,3-Diones Derivatives as Potential Disease-Modifying Multifunctional Anti-Alzheimer Agents

  2018cites this paper
• Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease.

  2017cites this paper
• Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.

  2017cites this paper
• Inhibition of Inflammation Mediated Through the Tumor Necrosis Factor α Biochemical Pathway Can Lead to Favorable Outcomes in Alzheimer Disease

  2017cites this paper
• Multitarget drug design strategy in Alzheimer's disease: focus on cholinergic transmission and amyloid-β aggregation.

  2017cites this paper
• Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer’s disease

  2017cites this paper
• Targeting β-amyloid plaques and oligomers: development of near-IR fluorescence imaging probes.

  2017cites this paper
• Targeting the Nrf2/Amyloid-Beta Liaison in Alzheimer's Disease: A Rational Approach.

  2017cites this paper
• Medicinal Chemistry of Hybrids for Neurodegenerative Diseases

  2017cites this paper
• Advances toward multifunctional cholinesterase and β-amyloid aggregation inhibitors.

  2017cites this paper
• New pyridine derivatives as inhibitors of acetylcholinesterase and amyloid aggregation.

  2017cites this paper
• Curcumin in Alzheimer's disease: Can we think to new strategies and perspectives for this molecule?

  2017cites this paper
• Journal of Intercultural Ethnopharmacology Assessment of In-vitro Cholinesterase Inhibitory and Thrombolytic Potential of Bark and Seed Extracts of Tamarindus Indica (l.) Relevant to the Treatment of Alzheimer's Disease and Clotting Disorders

  year unknowncites this paper